|Bid||69.53 x 900|
|Ask||69.56 x 2900|
|Day's range||68.75 - 69.64|
|52-week range||56.58 - 72.81|
|Beta (3Y monthly)||0.78|
|PE ratio (TTM)||21.00|
|Earnings date||18 Feb 2020 - 24 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||68.27|
We'd be surprised if Henry Schein, Inc. (NASDAQ:HSIC) shareholders haven't noticed that an insider, Paul Brons...
"We continue to make progress in growing organically with a focus on sales of higher-margin products while making strategic investments to supplement growth in the years ahead."
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Henry Schein, Inc. (HSIC) reminds its customers in California that the Henry Schein Disaster Relief Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by the ongoing fires. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 7 a.m. to 5 p.m. Central Time.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein, Inc. (HSIC), the world's largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the repurchase of up to $400 million of shares of the Company's common stock. The Company had approximately 147 million shares outstanding as of October 30, 2019. This new authorization represents approximately 4.0 percent of shares outstanding at the current stock price.
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.
Henry Schein, Inc. , the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the Credit Suisse 2019 Healthcare Conference at The Phoenician in Scottsdale, Arizona, on Tuesday, November 12, 2019, at 9:10 a.m.
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat third quarter 2019 view are likely to have contributed to Stryker's (SYK) Q3 earnings.
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Henry Schein, Inc. , the world's largest provider of health care products and services to office-based dental and medical practitioners, announced today that it will release its third quarter 2019 financial results before the stock market opens on Tuesday, November 5, 2019, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m.
Henry Schein, Inc. (HSIC) announced today that the plaintiff has agreed to dismiss the Company with prejudice as a defendant in the opioid litigation involving Summit County, Ohio, presently before the U.S. District Court for the Northern District of Ohio. “The opioid crisis is a terrible national tragedy, and all segments of society need to come together to address the crisis,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc. “We look forward to playing a constructive role in helping to advance solutions that put an end to opioid addiction.
Henry Schein, Inc. (HSIC) issued the following statement in response to a ruling released today by D. Michael Chappell, the Chief Administrative Law Judge of the U.S. Federal Trade Commission (link to decision), who dismissed claims that Henry Schein conspired with competitors to avoid providing discounts to, or to otherwise serve, buying groups representing dental practitioners. Henry Schein, Inc. (HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 19,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes.
Henry Schein, Inc. (HSIC) announced today that Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, received the National Network for Oral Health Access (NNOHA) President’s Award for his support of NNOHA as well as his personal, professional, and humanitarian accomplishments. Under Mr. Bergman’s leadership, Henry Schein played a pivotal role in helping to develop the organization during its inception in 1991. Mr. Bergman has continued to be a thought leader for inclusive health by recognizing the importance of NNOHA at its founding and supporting its goal of strengthening and expanding the nation’s oral health safety-net system.
A federal appeals court on Thursday cleared the way for a landmark trial over the nation's opioid crisis, rejecting a bid by eight drug retailers and distributors to disqualify the judge, and a request by Ohio and other U.S. states to delay an Oct. 21 trial. The 6th U.S. Circuit Court of Appeals in Cincinnati said U.S. District Judge Dan Polster, who oversees nationwide opioid litigation, had not created an appearance of bias against the drug industry through his rulings, public statements, and efforts to encourage settlements.
Eight drug companies on Tuesday urged a federal appeals court to disqualify the judge overseeing nationwide opioid litigation, in a last-ditch effort to avoid having him preside over a landmark trial in three weeks. The request came six days after U.S. District Judge Dan Polster in Cleveland refused to recuse himself and said he had done nothing to favor the state and local governments suing for damages, including by encouraging settlements. Polster oversees more than 2,300 of the roughly 2,600 lawsuits brought by state, local and tribal governments, hospitals and other entities seeking to hold the drug industry responsible for the toll of opioid abuse.
The U.S. judge overseeing nationwide opioid litigation on Thursday rejected a request by several big pharmacy chains and drug distributors to disqualify himself because he appeared to be biased against them and pressed too hard for a costly settlement. Companies that sought Polster's recusal included retailers CVS Health Corp, Rite Aid Corp, Walgreens Boots Alliance Inc and Walmart Inc, and distributors AmerisourceBergen Corp, Cardinal Health Inc, Henry Schein Inc and McKesson Corp.